-
Dec 21, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Nancy Reau |Mark S. Sulkowski
December 21, 2023Expert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care. TranscriptAnthony Martinez, MD: Mark, are you looking into the future? Are you excited about anything in whether treatment of hep[atitis][hepatitis] C or management of hep[atitis][hepatitis] C? Is there anything down the line that's got you excited? Mark Sulkowski, MD: Certainly, it's a very exciting time.
-
Dec 21, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Nancy Reau |Mark S. Sulkowski
December 21, 2023The panelists discuss challenges faced in HCV care, especially in addiction medicine and strategies to overcome them. TranscriptAnthony Martinez, MD: We’ve talked about implementing this into our practice. Sometimes it can be a difficult patient group because of certain aspects of patients’ lives that are simply their reality., [for example,] And things I'm thinking about specifically whether its active substance use or unstable housing.
-
Dec 14, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Nancy Reau |Mark S. Sulkowski
TranscriptAnthony Martinez, MD: I want to kind of just go around the table, andwhen we think about implementation of a program, …could each of you give me just some practical concepts that you feel are essential to implementing a program? Jordan Mayberry, MPAS, PA-C: I think much like Dr Khan was saying, it's really about empowering your APPs [advanced practice provider] as someone who can treat hepatitis C and not just in our GI and hepatology clinics.
-
Dec 14, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Mark S. Sulkowski
December 14, 2023Dr. Tipu Kahn gives an overview of various care models for HCV treatment. TranscriptAnthony Martinez, MD: Tipu, we've talked a lot about now screening, baseline workup, diagnosis, some of the medication regimens. We're going to move to implementing this into our clinical practice. Can you just give us an overview of what some of the basic models of care look like? Tipu V. Khan, MD: YeahYes,.
-
Dec 7, 2023 | 
contagionlive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Nancy Reau |Mark S. Sulkowski
TranscriptAnthony Martinez, MD: Mark, in the old days when we started a patient on therapy, we had to do a million different labs while they were on treatment to monitor blood counts and this and that. You’ve done extensive work in terms of minimal monitoring. Is there anything that we need to do with these newer regimens once they’re on treatment? Mark Sulkowski, MD: It’s a great question.
-
Dec 7, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Nancy Reau |Mark S. Sulkowski
December 7, 2023The panelists discuss adherence in HCV treatment. TranscriptAnthony Martinez, MD: We’ve seen in these high-risk groups, some of these options. The cure rate is essentially the same as in the general population, whether it’s in clinical trials or real-world data. We have a lot of information that this is a very treatable group of individuals, even when we’re talking about injection drug use. You talked, Mark, a little bit about provider bias.
-
Dec 7, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Nancy Reau |Mark S. Sulkowski
December 7, 2023Experts in HCV care discuss monitoring HCV treatment. TranscriptAnthony Martinez, MD: Mark, in the old days when we started a patient on therapy, we had to do a million different labs while they were on treatment to monitor blood counts and this and that. You’ve done extensive work in terms of minimal monitoring. Is there anything that we need to do with these newer regimens once they’re on treatment? Mark Sulkowski, MD: It’s a great question.
-
Nov 30, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Nancy Reau |Mark S. Sulkowski
November 30, 2023An overview of treatment regimens for HCV. Transcript Anthony Martinez, MD: Mark, you mentioned a little bit about how the therapeutics have evolved. Jordan, can you kind of give us a high-level overview of what we have available for patients today? Jordan Mayberry, MPAS, PA-C: Currently there are 2 different regimens in our treatment algorithm. I think it’s important to just reiterate that these medications are highly effective.
-
Nov 30, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Jordan Mayberry |Nancy Reau |Mark S. Sulkowski
November 30, 2023Expert hepatologist Mark Sulkowski, MD discusses which patients are candidates for HCV treatment. TranscriptAnthony Martinez, MD: OK, so we’ve diagnosed our patient we’ve done our baseline workup. That’s been pretty easy. Mark, who are you treating, who needs to be treated? And the second part of the question is, are you still differentiating between acute hepatitis C and chronic hepatitis C? Mark Sulkowski, MD: Well, it’s a really great question with a pretty simple answer.
-
Nov 27, 2023 | 
hcplive.com | Anthony Martinez |Tipu V Khan |Nancy Reau |Jordan Mayberry |Mark S. Sulkowski
TranscriptAnthony Martinez, MD: Screening’s gotten a little bit easier. The baseline workup has also gotten significantly easier. Tipu, in your setting, what baseline tests are you getting right now? Tipu V. Khan, MD: So like Nancy said, once we’ve got the reflex and the RNA back and we’ve confirmed hepatitis C [virus; HCV], it’s a bread-and-butter set of labs, labs that all of us use all the time in interpreting other disease states.
